Abstract: A multiple component hot gas flowing conduit has an elongated, convoluted bellows, an interlock liner, frequency dampers and elastic spacers engaging the dampers and biasing the dampers into respective bellows convolution with no contact of bellows and liner for all operating states of the conduit. Assembly pretension of the interlock liner preferably flattens out the elastic spacers permitting assembly of the liner into the bellows and upon relaxation of the liner, the spacers extend radially outwardly to engage and bias the dampers into the bellows. The bellows is convoluted throughout, or may have convoluted ends with an integral smooth-wall tube therebetween. Components are isolated from abrasion against one another.

Abstract: A multiple component hot gas flowing conduit has an elongated, convoluted bellows, an interlock liner, frequency dampers and elastic spacers engaging the dampers and biasing the dampers into respective bellows convolution with no contact of bellows and liner for all operating states of the conduit. Assembly pretension of the interlock liner preferably flattens out the elastic spacers permitting assembly of the liner into the bellows and upon relaxation of the liner, the spacers extend radially outwardly to engage and bias the dampers into the bellows. The bellows is convoluted throughout, or may have convoluted ends with an integral smooth-wall tube therebetween. Components are isolated from abrasion against one another.

Abstract: A transit system including a system data processor in communication with a driver data processor of a driver electronic device and a rider data processor of a rider electronic device. The system data processor receives vehicle information of a vehicle from the driver. data processor. The vehicle information includes a vehicle route and a geolocation of the vehicle. The system data processor receives a geolocation of a rider electronic device from the rider data processor, and sends the vehicle information and advertisement information over a communication network to the rider data processor. The advertisement information is based on the vehicle information and the geolocation of the rider electronic device.

Abstract: This invention provides novel chemically modified mutant serine hydrolases that catalyze a transamidation and/or a transpeptidation and/or a transesterification reaction. The modified serine hydrolases have one or more amino acid residues in a subsite replaced with a cysteine, wherein the cysteine is modified by replacing the thiol hydrogen in the cysteine with a substituent group providing a thiol side chain comprising a moiety selected from the group consisting of a polar aromatic substituent, an alkyl amino group with a positive charge, and a glycoside. In particularly preferred embodiments, the substitutents include an oxazolidinone, a C1 to C15 alkyl amino group with a positive charge, or a glycoside.

Abstract: This invention provides novel chemically modified mutant serine hydrolases that catalyze a transamidation and/or a transpeptidation and/or a transesterification reaction. The modified serine hydrolases have one or more amino acid residues in a subsite replaced with a cysteine, wherein the cysteine is modified by replacing the thiol hydrogen in the cysteine with a substituent group providing a thiol side chain comprising a moiety selected from the group consisting of a polar aromatic substituent, an alkyl amino group with a positive charge, and a glycoside. In particularly preferred embodiments, the substitutents include an oxazolidinone, a C1 to C15 alkyl amino group with a positive charge, or a glycoside.

Abstract: This invention provides novel chemically modified mutant serine hydrolases that catalyze a transamidation and/or a transpeptidation and/or a transesterification reaction. The modified serine hydrolases have one or more amino acid residues in a subsite replaced with a cysteine, wherein the cysteine is modified by replacing the thiol hydrogen in the cysteine with a substituent group providing a thiol side chain comprising a moiety selected from the group consisting of a polar aromatic substituent, an alkyl amino group with a positive charge, and a glycoside. In particularly preferred embodiments, the substitutents include an oxazolidinone, a C1 to C15 alkyl amino group with a positive charge, or a glycoside.

Abstract: This invention provides novel chemically modified mutant serine hydrolases that catalyze a transamidation and/or a transpeptidation and/or a transesterification reaction. The modified serine hydrolases have one or more amino acid residues in a subsite replaced with a cysteine, wherein the cysteine is modified by replacing the thiol hydrogen in the cysteine with a substituent group providing a thiol side chain comprising a moiety selected from the group consisting of a polar aromatic substituent, an alkyl amino group with a positive charge, and a glycoside. In particularly preferred embodiments, the substitutents include an oxazolidinone, a C1 to C15 alkyl amino group with a positive charge, or a glycoside.

Abstract: This invention provides novel chemically modified mutant serine hydrolases that catalyze a transamidation and/or a transpeptidation and/or a transesterification reaction. The modified serine hydrolases have one or more amino acid residues in a subsite replaced with a cysteine, wherein the cysteine is modified by replacing the thiol hydrogen in the cysteine with a substituent group providing a thiol side chain comprising a moiety selected from the group consisting of a polar aromatic substituent, an alkyl amino group with a positive charge, and a glycoside. In particularly preferred embodiments, the substitutents include an oxazolidinone, a C1 to C15 alkyl amino group with a positive charge, or a glycoside.

Abstract: This invention provides novel chemically modified mutant serine hydrolases that catalyze a transamidation and/or a transpeptidation and/or a transesterification reaction. The modified serine hydrolases have one or more amino acid residues in a subsite replaced with a cysteine, wherein the cysteine is modified by replacing the thiol hydrogen in the cysteine with a substituent group providing a thiol side chain comprising a moiety selected from the group consisting of a polar aromatic substituent, an alkyl amino group with a positive charge, and a glycoside. In particularly preferred embodiments, the substitutents include an oxazolidinone, a C1 to C15 alkyl amino group with a positive charge, or a glycoside.